Academic Origin Story
Physician Scientist C Vivek Lal MD FAAP, together with colleagues at the University of Alabama at Birmingham in the Pulmonary Microbiome Lab, Microbiome Center, Lung Health Center, and Translational Research in Normal and Disordered Development (TReNDD),has been studying the microbiome as it relates to lung health for over a decade.
Formulating the world’s first ResBiotic™
Over the last few years, Dr. Lal and his team developed and tested proprietary probiotic strains to support lung health. The strains have been tested independently, as a blend, and in combination with bioactive botanicals to develop an optimal formulation that supports lung structure and function.*
Dr. Lal founded ResBiotic™ in 2020 to make his innovation accessible to the public.
Introducing resB™ Lung Support
In October 2021, the company announced its first product, resB™ Lung Support: a science-backed probiotic supplement for gut, lung, and immune health.
At this time, the company also announced the spin out of pharmaceutical subsidiary Alveolus Bio. While ResBiotic remains focused on consumer health products, Alveolus Bio will pursue the development of breakthrough therapies for chronic lung disease.